
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics Inc. is experiencing strong sales momentum for its ophthalmic product, Lytenava, with unit sales reportedly doubling in the UK and Germany in 1Q26 compared to the previous quarter, indicating robust market demand. The company plans to expand its presence in key EU markets such as France, Italy, and Spain in 2027, which could further enhance revenue growth prospects. Despite a narrowed operating loss and ongoing FDA approval anticipation for ONS-5010, the current market price is seen as significantly undervalued, suggesting considerable upside potential for shareholders.
Bears say
Outlook Therapeutics Inc has experienced a significant decline in research and development (R&D) expenses, dropping 62.4% year-over-year to $3.6 million, which raises concerns about the company's ability to sustain its development pipeline. General and administrative (G&A) expenses also fell by 27.9% to $8.6 million, yet they still exceeded expectations, indicating a potential misalignment in cost management. Furthermore, the declining market for ophthalmic treatments, including an approximately 12-month price drop in the US ranibizumab market, suggests challenges for the commercialization of ONS-5010, while the company’s reliance on a single development program heightens the risk of negative outcomes from both market dynamics and clinical trials.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares